10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
Fabio Efficace(Fondazione Gimema Onlus), Michael Luebbert(University Medical Center Freiburg), Robin Foà(Sapienza University of Rome), Frédéric Baron(University of Liège), Eduardus F. M. Posthuma(Leiden University Medical Center), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Walter JFM van der Velden(Radboud University Nijmegen), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Gerwin Huls(University Medical Center Groningen), Corneel Coens(European Organisation for Research and Treatment of Cancer), Andrea Mengarelli(Istituti di Ricovero e Cura a Carattere Scientifico), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stephan Fuhrmann(Helios Hospital Berlin-Buch), Radovan Vrhovac(University Hospital Centre Zagreb), Andreas Neubauer(RWTH Aachen University), Stefan Suciu(European Organisation for Research and Treatment of Cancer), Laimonas Griškevičius(Vilnius University), Marco Vignetti(Fondazione Gimema Onlus), Richard Noppeney(Essen University Hospital), Martina Crysandt(RWTH Aachen University), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Olivier Legrand(Inserm), P. W. Wijermans(Haga Hospital), Anna Candoni(University of Udine), Adriano Venditti(University of Rome Tor Vergata), Mario Luppi(University of Modena and Reggio Emilia)
Cited by 3
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k